

INTERNATIONAL JOURNAL OF

211

Radiation Oncology

BIOLOGY • PHYSICS

VOLUME 51, NUMBER 3

NOVEMBER 1, 2001



WESTON LIBRARY

NOV 02 2001

J5/120 CLINICAL SCIENCE CENTER
600 HIGHLAND AVE MADISON WI 53792

The Official Journal of the American Society for Therapeutic Radiology and Oncology

Sponsored by the
INTERNATIONAL SOCIETY OF RADIATION ONCOLOGY
CIRCULO DE RADIOTERAPEUTAS IBERO-LATINOAMERICANOS
AMERICAN BRACHYTHERAPY SOCIETY



ELSEVIER
ISSN 0360-3016

Visit IJROBP Online at www.elsevier.com/locate/ijrobp

DOCKET
ALARM

Find authenticated court documents without watermarks at docketalarm.com.

Aims and Scope: The *International Journal of Radiation Oncology•Biology•Physics (IJROBP)* publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, and medical physics. It is a condition of publication that manuscripts submitted to the *IJROBP* have not been published and will not be simultaneously submitted or published elsewhere. All manuscripts submitted to the *IJROBP* are subject to peer review and only those that are of the highest scientific quality are accepted for publication. **Instructions for Contributors** are printed in the January issue each year and can also be found online at <http://www.elsevier.com/locate/ijrobonline>.

Editorial Office: Please forward manuscript submissions for *IJROBP* to: James D. Cox, M.D., Editor-in-Chief, *IJROBP*, Department of Scientific Publications, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030; (713) 792-6014.

Publishing Office: Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010, USA, Email Address: ESUK.USA@ELSEVIER.COM.

For Advertising Orders & Inquiries, North & South America: Tino DeCarlo, Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010. Tel: (212) 633-3686; Fax: (212) 633-3820. **International:** Advertising Department, Elsevier Science, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom. Tel: (+44) (0) 1865 843565; Fax: (44) (0) 1865 843976; E-mail: media@elsevier.co.uk **Japan:** Advertising Department, Elsevier Science Japan, Tel: (81) (3) 5561 5033; Fax: (81) (3) 5561 5047.

Published 15 per annum (vols. 49–51). *Annual Institutional Subscription Rate* (2001): For customers in Europe, The CIS and Japan: Institutional Rate: NLG 5,254.00, Personal Rate NLG 867.00, Student/Resident Rate: NLG 98.00. For customers in all other Countries: Institutional Rate: US\$ 2,667.00, Personal Rate: US\$ 440.00. Student/Resident Rate: US\$ 50.00. Prices include postage and are subject to change without notice. Any inquiry relating to subscriptions should be sent to: **The Americas:** Elsevier Science, Customer Support Department, P.O. Box 945, New York, NY 10010, USA. [Tel: (+1) 212-633-3730/1-888-4ES-INFO. Fax: (+1) 212-633-3680. E-mail: usinfo-f@elsevier.com]. **Japan:** Elsevier Science, Customer Support Department, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan [Tel: (+3) 5561-5033. Fax: (+3) 5561-5047. E-mail: kyf04035@niftyserve.or.jp]. **Asia Pacific (excluding Japan):** Elsevier Science (Singapore) Pte Ltd, No. 1 Teck Seng Avenue, 17-01 Millenia Tower, Singapore 039192. [Tel: (+65) 434-3727. Fax: (+65) 337-2230. E-mail: asiainfo@elsevier.com.sg]. **Rest of the World:** Elsevier Science, Customer Service Department, P.O. Box 211, 1001 AE Amsterdam, The Netherlands. [Tel: (+31) 20-485-3757. Fax: (+31) 20-485-3432. E-mail: nlinfo-f@elsevier.nl]. Elsevier Science, Rua Sete de Setembro 111/16 Andar, 20050-002 Centro, Rio de Janeiro-RJ, Brazil; phone: (+55) (21) 509 5340; fax: (+55) (21) 507 1991; e-mail: elsevier@campus.com.br [Note (Latin America): for orders, claims and help desk information, please contact the Regional Sales Office in New York as listed above].

Reprints of any article in this journal are available for purchase in quantities of 100 or more. Please contact Inez Herrero, Commercial Reprints Dept., Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010-5107. Email: i.herrero@elsevier.com; Tel: (212) 633-3874; Fax: (212) 633-3820.

Copyright © 2001 Elsevier Science Inc.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

Photocopying. Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions. Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.co.uk. You may also contact Rights & Permissions directly through Elsevier's home page (<http://www.elsevier.nl>), selecting first 'Customer Support', then 'General Information', then 'Permissions Query Form'. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 171 436 5931; fax: (+44) 171 436 3986. Other countries may have a local reprographic rights agency for payments.

Notice. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the sole responsibility of the contributor or advertiser concerned. Accordingly, the publishers, the editorial board and editors and their respective employees, officers and agents accept no responsibility of liability whatsoever for the consequences of any such inaccurate or misleading data, opinions or statement.

Drug and dosage selection: The authors have made every effort to ensure the accuracy of the information herein, particularly with regard to drug selection and dose. However, appropriate information sources should be consulted, especially for new or unfamiliar drugs or procedures. It is the responsibility of every practitioner to evaluate the appropriateness of a particular opinion in the context of actual clinical situations and with due consideration to new developments.

Disclaimer—The American Society for Therapeutic Radiology and Oncology assumes no responsibility for the accuracy of any editorial material contained in this Journal, and such editorial material does not represent official policy or recommendations of the Society. The appearance of advertising in this Journal does not constitute a guarantee or endorsement by the Society of the quality or value of any advertised products or services or of the claims made for them by the advertisers.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY•BIOLOGY•PHYSICS (ISSN 0360–3016) is published monthly, semi-monthly in March, July, and November for \$2,667 Institutional; \$440 Personal; \$50 Student/Resident by Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010-5107. Periodicals postage paid at New York, NY, and additional mailing offices. Postmaster: send address changes to **International Journal of Radiation•Oncology•Biology•Physics**, Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010-5107, USA.

standard multileaf collimator by one or two steps of 20 when using multiple non-coplanar fields, there is no need for 3-mm micro-multileaf collimator in order to treat either spherical or complex GTVs.

Situation	V _{95%} - V _{GTV}
One sphere (22.5-mm diameter) using 3-mm micro-multileaf collimator and 5 non-coplanar fields	0.000 ml
One sphere (22.5-mm diameter) using 9-mm standard multileaf collimator and 5 non-coplanar fields without collimator rotation	0.008 ml
One sphere (22.5-mm diameter) using 9-mm standard multileaf collimator and 5 non-coplanar fields with one collimator rotation of 20°	0.008 ml
Two spheres (15-mm diameter) using 3-mm micro-multileaf collimator and 5 non-coplanar fields	0.050 ml
Two spheres (15-mm diameter) using 9-mm standard multileaf collimator and 5 non-coplanar fields without collimator rotation	0.060 ml
Two spheres (15-mm diameter) using 9-mm standard multileaf collimator and 5 non-coplanar fields with one collimator rotation of 20°	0.056 ml

2299 Development of a New Linear Accelerator Mounted with Dual X-Ray Fluoroscopy Using Amorphous Silicon Flat Panel X-Ray Sensors to Detect a Gold Seed in a Tumor at Real Treatment Position

Y. Takai¹, M. Mitsuya¹, K. Nemoto¹, Y. Ogawa¹, H. Matsusita¹, S. Yamada¹, H. Mostafavi², M. Marc², A. Jeung², S. Manfield²

¹Radiation Oncology, Tohoku University, Sendai, Japan, ²Ginzton Technology Center, VARIAN Medical Systems, Mountain View, CA

Purpose: Set-up error and organ motion interferes with the accuracy of radiotherapy for extracranial tumors. We usually take a linacgram for verification of irradiation field, because the set-up accuracy is usually no better than 1.0 cm for body tumors. In the stereotactic radiotherapy, the position and movement of tumors should be detected before every treatment. Linacgram is not suitable for the verification of stereotactic irradiation, because tumors (or gold seeds in the tumors) in the lower lung, liver or abdominal organ is not detected by that. So the purpose of this study is to develop the linear accelerator mounted with two fluoroscopy, using recently developed amorphous silicon (a-SI) flat panel to detect tumor position and movement for better daily positioning accuracy after a setup of a patient on the couch of the linear accelerator.

Materials and Methods: Clinac 23EX (Varian Medical Systems) was mounted with dual X-ray generators (RAD II simulator: Haynes Radiation Ltd.) on the gantry with a 90 degree angle (each one was mounted at ±45 degree from the beam axis of the Clinac). The range of output kVp of this X-ray generator is 40 to 150 in 1 kVp increments digitally displayed, and exposure time is 8 ms to 10 seconds. Two sets of a-SI flat panel X-ray sensor (PaxScan 2520: Varian Medical Systems) were also mounted on the gantry at just the opposite places of the X-ray generators. The size of this flat panel and its imaging area are 16.6 x 25.8 cm and 7.1 x 9.4 cm, respectively. The images from this sensor were obtained as 15 frames per second, and outputted as digital video signals.

The image of a gold seed on a rotating disk or in a metastatic lung cancer of a patient with Ewing tumor was tried to be detected with these dual a-SI flat panel X-ray sensors. The size of rod shaped gold seed is 0.8 mm in diameter and 3 mm in length. This gold seed is implanted into the tumor of a patient using disposable sterile needle of which a gold seed is charged in the tip.

Results: A picture of newly developed linear accelerator mounted with a dual fluoroscopy using a-SI flat panel X-ray sensors is shown in Figure 1. The images of gold seed on a rotating disk and in the lung cancer were clearly obtained by this system.

Conclusion: The new linear accelerated system developed in this present study seems to be very useful for the set-up of a patient, and to verify the irradiation field just before irradiation. This helps to lessen the systematic error that is caused by body movement of a patient and so on. We are now investigating continuous monitoring of the tumor movement during irradiation using this new system.

